CD274 and neoplasm: The most promising markers currently under study comprise microsatellite instability (MSI), high tumor mutational load (TML) (83, 84), mismatch repair deficiency (dMMR) (85), HLA class-I diversity (86, 87), and biomarker expression (e.g., PD1, PD-L1) (88).